01 4Ofev
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 2,448
2019 Revenue in Millions : 1,776
Growth (%) : 38
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 2,743
2020 Revenue in Millions : 2,448
Growth (%) : 21
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 3,498
2021 Revenue in Millions : 2,743
Growth (%) : 28
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2023 Revenue in Millions : 3,735
2022 Revenue in Millions : 3,498
Growth (%) : 9
